title: Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients.
abstract: OBJECTIVE
  The purpose of this study was to explore the population pharmacokinetic features of moxifloxacin in infected patients.
  
  
  METHODS
  A total of 37 Chinese adult infected patients were treated with intravenous moxifloxacin (400 mg/day). In total, 67 plasma samples of moxifloxacin were collected immediately after intravenous dripping and before administration on the 3rd, 4th or 5th day. A nonlinear mixed effect model was used to model the population pharmacokinetic (PK) behavior of moxifloxacin. The final population pharmacokinetic models were validated using the bootstrap method. Some covariates, including demographic characteristics and hematological and biological indicators, were analyzed.
  
  
  RESULTS
  A structural model was developed based on a one-compartment model with intravenous infusion and first-order elimination. The typical population values of moxifloxacin for the pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 12.9 L/h and 115 L, respectively. The inter-individual variabilities of CL and V were 36% and 28%, respectively. The covariates of WT influenced the CL and V values determined by the final model.
  
  
  CONCLUSIONS
  The present study developed population pharmacokinetic models for moxifloxacin in infected Chinese patients. The results detailed here could provide a reference for individualized moxifloxacin therapy in the clinical setting.
authors.affiliation: Tianjin First Center Hospital, Tianjin 300192, China. Electronic address: zlq0713@aliyun.com.
authors.forename: Liqin
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Tianjin Third Central Hospital, Tianjin 300170, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Wang
authors.affiliation: Tianjin First Center Hospital, Tianjin 300192, China.
authors.forename: Wenjie
authors.initials: W
authors.lastname: Yang
authors.affiliation: Tianjin First Center Hospital, Tianjin 300192, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Tianjin First Center Hospital, Tianjin 300192, China.
authors.forename: Xuequn
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Peking University, Beijing 100871, China.
authors.forename: Shuangmin
authors.initials: S
authors.lastname: Ji
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D000077266:Moxifloxacin; D017711:Nonlinear Dynamics; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin
keywords: Infected patients; Moxifloxacin; Nonlinear mixed-effect model; Population pharmacokinetic model